Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
Status:
Completed
Trial end date:
2019-10-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical benefit rate at 12 weeks from the
addition of pazopanib to a non-steroidal aromatase inhibitor (NSAI) (letrozole or
anastrozole) in patients with hormone receptor positive advanced breast cancer progressing on
the same NSAI hormone therapy.